Anaplastic meningioma
diseaseOn this page
Also known as anaplastic (malignant) meningiomamalignant meningiomameningioma, anaplastic, malignant
Summary
Anaplastic meningioma (MONDO:0020635) is a disease and 13 clinical trials. Top therapeutic interventions include bevacizumab, sonidegib, and onc-206. A subtype of anaplastic cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 13
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anaplastic meningioma |
| Mondo ID | MONDO:0020635 |
| NCIT | C4051 |
| UMLS | C0259785 |
| MedGen | 75478 |
| GARD | 0025191 |
| Is cancer (heuristic) | no |
Also known as: anaplastic (malignant) meningioma · anaplastic meningioma · malignant meningioma · meningioma, anaplastic, malignant
Data availability: 1 cell line.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › anaplastic cancer › anaplastic meningioma
Related subtypes (7): central nervous system anaplastic large cell lymphoma, sarcomatoid carcinoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic ependymoma, anaplastic oligoastrocytoma, primary cutaneous anaplastic large cell lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 13.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 5 |
| Not specified | 4 |
| PHASE2 | 3 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02847559 | PHASE2 | RECRUITING | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma |
| NCT03016091 | PHASE2 | TERMINATED | A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma |
| NCT03173950 | PHASE2 | COMPLETED | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers |
| NCT04541082 | PHASE1 | RECRUITING | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms |
| NCT01082926 | PHASE1 | COMPLETED | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 |
| NCT01144247 | PHASE1 | COMPLETED | Cellular Immunotherapy Study for Brain Cancer |
| NCT01151670 | PHASE1 | COMPLETED | Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors |
| NCT03434262 | PHASE1 | COMPLETED | SJDAWN: St. Jude Children’s Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors |
| NCT07172178 | EARLY_PHASE1 | NOT_YET_RECRUITING | γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma |
| NCT04501705 | Not specified | RECRUITING | Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults |
| NCT05793034 | Not specified | RECRUITING | Predictive Factors for Survival in Aggressive Meningiomas |
| NCT07552233 | Not specified | RECRUITING | NK Cell Therapy for Malignant Solid Brain Tumors |
| NCT02973256 | Not specified | UNKNOWN | Oncological Care for Patients With Meningioma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 1 |
| SONIDEGIB | 4 | 1 |
| ONC-206 | 1 | 1 |
Related Atlas pages
- Drugs: Bevacizumab, Sonidegib